News | July 18, 2022
China Pharma submits plan of compliance to NYSE American
The company was directed to submit a plan of compliance by July 15, 2022
The company was directed to submit a plan of compliance by July 15, 2022
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
The study demonstrated that patients who received NONS had significant reduction in viral load within 24 hours, which was sustained over seven days of treatment.
EVERSANA and Compai Pharma will provide medical and commercial resources to healthcare partners
Plant is part of the company's CAD $30 million capital investment in the site
MINYM can be safely used by patients above 9 years of age.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The combined company will be able to better serve both our global and regional customers with local production
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
Subscribe To Our Newsletter & Stay Updated
